Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
OGN is expected to report earnings to fall 10.08% to 90 cents per share on February 12
Q4'25
Est.
$0.91
Q3'25
Beat
by $0.07
Q2'25
Beat
by $0.06
Q1'25
Beat
by $0.11
Q4'24
Missed
by $0.01
The last earnings report on November 10 showed earnings per share of $1.01, beating the estimate of 93 cents. With 6.08M shares outstanding, the current market capitalization sits at 1.98B.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. OGN showed earnings on November 10, 2025. You can read more about the earnings report here.